-
Mashup Score: 0Similar reduction in CV risk with different add-on RA treatments - 2 year(s) ago
Among patients with active rheumatoid arthritis, adding tumor necrosis factor inhibitors to methotrexate is associated with a similar reduction in vascular inflammation to that seen with add-on sulfasalazine plus hydroxychloroquine, suggest findings from a randomized controlled trial.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Bimekizumab beneficial for psoriatic arthritis in phase 3 trials - 2 year(s) ago
Bimekizumab has shown positive efficacy and safety results in the BE COMPLETE and BE OPTIMAL phase 3 psoriatic arthritis trials.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
BE COMPLETE & BE OPTIMAL trials published in @TheLancet suggest benefits of #bimekizumab in patients with #PsoriaticArthritis. Click through to read more about the studies & watch our interview with @JosephMerolaMD https://t.co/bSQkYjjfng
-
-
Mashup Score: 0
Philippe Carron comments on the findings from the BE COMPLETE and BE OPTIMAL studies, and discusses how bimekizumab may impact the psoriatic arthritis treatment landscape if approved by the regulatory authorities.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
And here's our interview with @PhilippeCarron, who comments on the BE COMPLETE & BE OPTIMAL findings and discusses how #bimekizumab may impact the PsA treatment landscape 👉https://t.co/JnUFgx35N5👈 https://t.co/Q9S8h8MBtN
-
-
Mashup Score: 0
People with late-onset rheumatoid arthritis have a similar likelihood of achieving remission as those with earlier-onset disease, indicating that treatment goals should be the same in both populations, researchers report.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
This week's top story: Treatment goals in late-onset #RheumatoidArthritis should match those for younger patients #RheumTwitter @ArthritisRes https://t.co/5SiZ1WlLdu
-
-
Mashup Score: 1The metabolic syndrome may influence the risk for gout - 3 year(s) ago
The metabolic syndrome may be a modifiable risk factor for incident gout, suggest findings from a nationwide study of more than 1.29 million men.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News: The metabolic syndrome and its recovery influences the risk for #gout, report researchers, who highlight the need for its management in young men @ACR_Journals https://t.co/T5223YCrjc
-
-
Mashup Score: 1
People with late-onset rheumatoid arthritis have a similar likelihood of achieving remission as those with earlier-onset disease, indicating that treatment goals should be the same in both populations, researchers report.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
News: People with late-onset #RheumatoidArthritis have a similar likelihood of achieving remission as those with earlier-onset disease, shows research from Claire Bombardier (@UofT) and team https://t.co/5SiZ1W49OU
-
-
Mashup Score: 1SURPASS: Secukinumab vs adalimumab biosimilar in axSpA - 3 year(s) ago
Xenofon Baraliakos takes us through SURPASS, a phase 3b head-to-head trial that demonstrated equivalence of secukinumab versus adalimumab biosimilar in patients with radiographic axial spondyloarthritis.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
#ACR22 video interview: Xenofon Baraliakos (@ruhrunibochum) talks about SURPASS, a phase 3b head-to-head trial of secukinumab versus adalimumab biosimilar in radiographic axSpA – click through to watch https://t.co/cKmQRoGLpd
-
-
Mashup Score: 1LOUiSSe study shows remibrutinib efficacy in Sjögren’s syndrome - 3 year(s) ago
Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, has shown potential for the treatment of Sjögren’s syndrome in a phase 2 study.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
#ACR22 news: Thomas Dörner (@ChariteBerlin) & team report phase 2 results showing reduced disease activity with the BTK inhibitor remibrutinib over placebo in #SjögrensSyndrome https://t.co/FDcnJCmKpa
-
-
Mashup Score: 1
Patients with rheumatic diseases have reported issues with access to methotrexate following changes to abortion laws, show findings from a questionnaire study conducted in the USA.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
#ACR22 news: Patients with rheumatic diseases have reported issues with access to #methotrexate following changes to abortion laws in the USA, show study results #RheumTwitter https://t.co/DN2YnAvYtv
-
-
Mashup Score: 0New score could predict ILD development in people with SSc - 3 year(s) ago
Researchers have developed the ILD-RISC score, which has the potential to predict the development of interstitial lung disease in patients with systemic sclerosis.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
#ACR22 news in brief: The ILD-RISC score could predict the development of interstitial lung disease in patients with systemic sclerosis and help avoid unnecessary HRCT scans, report @CosimoBruni (@UNI_FIRENZE) & team https://t.co/hlzFae8y74
-
This week's top story: Similar reduction in cardiovascular risk with different add-on #RheumatoidArthritis treatments – click through to read more about the research findings from @DanielHSolomon (@BrighamWomens) & team published in @ARD_BMJ #RheumTwitter https://t.co/ZNYTcY3Ta2